Abstracts

28 – Systems Vaccinology

Although the development of effective vaccines has saved countless lives from infectious diseases, the basic workings of the human immune system are complex and have required the development of animal models, such as inbred mice, to define mechanisms of immunity. However, past results are not necessarily a reliable guide to the future, and a notable…

22 – HIV Care Continuum in Children

Children aged 0-15 years lag behind adults in achieving HIV treatment goals across HIV testing, initiation of antiretroviral therapy and viral suppression. While early diagnosis of pediatric HIV has scaled up significantly, children continue to slip through the cracks and remain undiagnosed and untreated. For children living with HIV, challenges in adherence to treatment is…

51 – We’ll Come to You: A Mobile Clinic Preexposure Prophylaxis Delivery Model

Effective HIV prevention requires well-designed and well-targeted services tailored according to client characteristics and needs. PrEP biomedical product choice allows young people to select a formulation that works for them and their lifestyle, while HIV prevention impact may be even greater if PrEP service delivery models also match young people’s diverse lifestyles and unique needs.…

27 – HIV Acquisition and Prevention During Pregnancy and Postpartum

This presentation will discuss HIV incidence during pregnancy and breastfeeding as well as factors (hormonal, immunological, behavioural, sexual and genital infections, and low male participation in antenatal care and HIV testing) that increase risk of HIV acquisition this period.  In addition, we will look at the contribution of acute HIV infection to vertical HIV infection…

6 – Liver Steatosis: New Nomenclature, New Tests, and New Drugs

This case-based session will address the most common cause of liver disease namely metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the overlapping entity MetALD. The audience will become familiar with the new nomenclature, epidemiology, clinical diagnosis, and risk-stratification using non-invasive tests. In addition, practical approaches to MASLD treatment including newly approved…

19 – Cellular and Tissue Sources of Viral Persistence and Rebound

Cellular and tissue sources of viral rebound primarily originate from long-lived reservoirs of HIV in individuals under antiretroviral therapy (ART). Key cellular reservoirs include CD4+ T cells, particularly memory subsets like central memory (Tcm), which harbor latent provirus. Tissue-specific sources include lymphoid tissues (lymph nodes, spleen, and gut-associated lymphoid tissue), where virus can persist despite…

47 – Dolutegravir Resistance: What Are the Implications for Antiretroviral Therapy Programs?

Introduction DTG-based regimens have simplified management for providers: Resistance to 1st-line DTG-based regimens is still incredibly rare. Therefore limited role for resistance testing in this scenario; can mostly assume non-adherence if viral load elevated. Fewer resistance tests required; less unnecessary switching drug classes, esp. in LMIC.  “Blind” switching to DTG-based regimens without requiring a resistance…